Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Dirks, Nathanael L.
19  Ergebnisse:
Personensuche X
?
1

Exposure–efficacy relationship of vedolizumab subcutaneous ..:

D'Haens, Geert ; Rosario, Maria ; Polhamus, Daniel...
Expert Review of Clinical Pharmacology.  17 (2024)  4 - p. 403-412 , 2024
Link: https://doi.org/10.1080/..
 
?
2

Population pharmacokinetics of vedolizumab in Asian and non..:

Okamoto, Hiroyuki ; Dirks, Nathanael L. ; Rosario, Maria..
Intestinal Research.  19 (2021)  1 - p. 95-105 , 2021
Link: https://doi.org/10.5217/..
 
?
3

Sa1868 AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP ..:

Chen, Chunlin ; Rosario, Maria ; Polhamus, Daniel...
Gastroenterology.  158 (2020)  6 - p. S-458 , 2020
Link: https://doi.org/10.1016/..
 
?
4

Vedolizumab exposure levels and clinical outcomes in ulcera..:

Osterman, Mark T. ; Rosario, Maria ; Lasch, Karen...
Alimentary Pharmacology & Therapeutics.  49 (2019)  4 - p. 408-418 , 2019
Link: https://doi.org/10.1111/..
 
?
5

Vedolizumab-A Case Example of Using Quantitative Pharmacolo..:

, In: Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases,
Rosario, Maria ; Dirks, Nathanael L. ; Mould, Diane R.... - p. 363-387 , 2019
Link: https://doi.org/10.1002/..
 
?
6

Corrigendum: Exposure—efficacy Relationships for Vedolizuma..:

Rosario, Maria ; French, Jonathan L ; Dirks, Nathanael L...
Journal of Crohn's and Colitis.  12 (2018)  4 - p. 510-510 , 2018
Link: https://doi.org/10.1093/..
 
?
7

A Review of the Clinical Pharmacokinetics, Pharmacodynamics..:

Rosario, Maria ; Dirks, Nathanael L. ; Milch, Catherine...
Clinical Pharmacokinetics.  56 (2017)  11 - p. 1287-1301 , 2017
Link: https://doi.org/10.1007/..
 
?
8

Model-based clinical pharmacology profiling and exposure-re..:

Zhu, Rui ; Zheng, Yanan ; Dirks, Nathanael L....
Pulmonary Pharmacology & Therapeutics.  46 (2017)  - p. 88-98 , 2017
Link: https://doi.org/10.1016/..
 
?
9

Exposure–efficacy Relationships for Vedolizumab Induction T..:

Rosario, Maria ; French, Jonathan L ; Dirks, Nathanael L...
Journal of Crohn's and Colitis.  11 (2017)  8 - p. 921-929 , 2017
Link: https://doi.org/10.1093/..
 
?
10

Mo1225 Population Pharmacokinetic Modeling of Vedolizumab i..:

Dirks, Nathanael L. ; Rosario, Maria ; Gastonguay, Marc R...
Gastroenterology.  146 (2014)  5 - p. S-591 , 2014
Link: https://doi.org/10.1016/..
 
?
11

Mo1229 Exposure-Response Relationship of Vedolizumab Treatm..:

French, Jonathan ; Rosario, Maria ; Dirks, Nathanael L....
Gastroenterology.  146 (2014)  5 - p. S-592 , 2014
Link: https://doi.org/10.1016/..
 
?
12

Mo1231 Vedolizumab Exposure-Response Relationship During In..:

French, Jonathan ; Rosario, Maria ; Dirks, Nathanael L....
Gastroenterology.  146 (2014)  5 - p. S-592-S-593 , 2014
Link: https://doi.org/10.1016/..
 
?
13

Population Pharmacokinetics of Therapeutic Monoclonal Antib..:

Dirks, Nathanael L. ; Meibohm, Bernd
Clinical Pharmacokinetics.  49 (2010)  10 - p. 633-659 , 2010
Link: https://doi.org/10.2165/..
 
?
14

O-003 Relationship Between Vedolizumab Pharmacokinetics and..:

Maria, Rosario ; Brihad, Abhyankar ; Serap, Sankoh...
Inflammatory Bowel Diseases.  20 (2014)  - p. S1-S3 , 2014
Link: https://doi.org/10.1097/..
 
?
15

Vedolizumab exposure levels and clinical outcomes in ulcera..:

Osterman, Mark T ; Rosario, Maria ; Lasch, Karen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590294/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
1-15